Tags : Acquisition

StageBio Acquires TPL Path Labs to Expand its Footprints Globally

Shots: StageBio and TPL Path Labs offers an expanded array of histopathology, molecular pathology, and related solutions to biopharma, medical device and academic researchers across the US, EU, and other countries The acquisition expands StageBio’s pre/ clinical laboratory resources, GLP/GCLP-compliant lab facility and staff in Germany tits existing 6 GLP-compliant lab facilities and 2 GLP […]Read More

Elanco Receives the US FTC’s Approval for Acquisition of Bayer

Shots: Elanco has received the US FTC’s approval for its acquisition of Bayer Animal Health, representing the final antitrust clearance needed to complete the transaction, which continues track for closing at the beginning of August The FTC’s approval follows divestiture of global rights for Osurnia to treat otitis externa in dogs, US rights for Capstar […]Read More

Danaher Receives S.Korean FTC’s Conditional Approval for its $21.4B GE

Shots: South Korea’s FTC has approved Danaher’s $21.4 billion acquisition of GE biopharma on condition that the companies will sell eight bioprocessing product assets addressing monopoly concerns The FTC’s approval follows EU’s conditional approval received in Dec 2019 after it agrees to sell five businesses to address worries about competition In Feb’2019, Danaher announced the […]Read More

Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the

Shots: BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly In Jan’2019, BMS announced to acquire Celgene with its expected closing of the transaction in H2’19 or H1’20. The divestiture of Otezla will accelerate BMS post-closing deleveraging plans Otezla is a PDE4 inhibitor, […]Read More

MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

Shots: Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for neurological disorders AAV-GAD is a gene therapy candidate delivering glutamic acid decarboxylase (GAD) gene, currently in P-II for Parkinson’s Disease and has also received FTD […]Read More

Roche Acquires Tusk Therapeutics for $81. 24 M (€70M) for

Shots: Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones Roche plans to continue the development of novel Ab developed by Tusk for depleting regulatory T-cells. The program is expected to hit the clinics by Q4’19 for cancer patients Tusk’s Spinout Black Belt Therapeutics, will hold […]Read More

Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities

Shots: ACEA to receive $250M in upfront cash as a total deal value, adding a differentiated portfolio and organizational capabilities in cell analysis Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration, i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth, function, and cellular responses of cells The […]Read More